Effect of Targeting Janus Kinase 3 on the Development of Intestinal Tumors in the Adenomatous Polyposis Colimin Mouse Model of Familial Adenomatous Polyposis
| Autor: | Fatih M. Uckun, Alexei O. Vassilev, Douglas Erbeck, Sanjive Qazi, Taracad K. Venkatachalam, Heather E. Tibbles |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Pathology medicine.medical_specialty Tumor suppressor gene Colorectal cancer Adenomatous polyposis coli medicine.disease_cause Avian sarcoma virus Familial adenomatous polyposis Mice Intestinal Neoplasms Drug Discovery medicine Animals Point Mutation Tissue Distribution Enzyme Inhibitors Chromatography High Pressure Liquid beta Catenin biology Janus kinase 3 Janus Kinase 3 medicine.disease Survival Analysis Mice Inbred C57BL Adenomatous Polyposis Coli Quinazolines biology.protein Cancer research Carcinogenesis Tyrosine kinase |
| Zdroj: | Arzneimittelforschung. 57:320-329 |
| ISSN: | 1616-7066 0004-4172 |
| Popis: | Familial adenomatous polyposis (FAP) is associated with germ-line mutations in the tumor suppressor gene, adenomatous polyposis coli (APC) located on chromosome 5q21. Multiple intestinal neoplasia (Min) in mice resembles FAP in humans, resulting from a single point mutation in the murine homolog of the APC gene. The effects of the rationally-designed Janus kinase 3 (JAK3) inhibitor JANEX-1 (4-(4'-hydroxyphenyl) amino-6,7-dimethoxy-quinazoline,WHI-P131, CAS 202475-60-3) on the development of intestinal tumors in the APC (min/+) mouse model of FAP were examined. The Min mice were fed with rodent chow or chow supplemented with JANEX-1 once a week starting at 1.5 months of age. The cumulative proportions of mice remaining alive at 7 months were 13 ± 6% for control mice versus 72 ± 12% for JANEX-1 treated mice (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|